Bluemtec

BlueMTec operates its core business through BluePharmKorea, an online B2B e-commerce platform that sells prescription drugs and medical supplies to clinics and hospitals, and has positioned itself as the leading online prescription drug e-commerce platform for clinics in Korea.

The company also runs additional distribution platforms such as CoolPharm, targeting pharmacies, giving it a structure that spans both clinic and pharmacy channels.

More recently, it launched BlueDoc, a medical staff recruiting platform, aiming to improve convenience for clinics and independent physicians based on its medical institution database and know-how.

Revenue is broken down into non-reimbursed, vaccine, reimbursed, quasi-drug, and service segments; as of the first half of 2025 comparison point, the mix was approximately 36% non-reimbursed, 31% vaccine, 18% reimbursed, 12% quasi-drug, and 2% service, while on a full-year 2025 basis the vaccine segment held the largest share at 43%.

However, with GLP-1 obesity drugs such as Wegovy joining the lineup, non-reimbursed revenue has grown sharply, shifting the portfolio increasingly toward the non-reimbursed category.

The company has long distributed aesthetics products from Hugel, LG Chem, and Medytox through its non-reimbursed segment, and has continued expanding this lineup through a filler and skin booster distribution agreement with Bio-Plus and the start of distribution for Medytox (Neume Co.) toxin products and new items.

Beyond Novo Nordisk's Wegovy and Saxenda, BlueMTec also participates in part of the distribution of Eli Lilly's Mounjaro, though Eli Lilly Korea has direct supply contracts with a separate group of 30 to 40 distributors including Geo Young, meaning BlueMTec does not hold an exclusive position there.

Korea's pharmaceutical distribution market remains concentrated among large wholesalers, and BlueMTec is pursuing a strategy of strengthening its market position through differentiated online platform services and a broad product lineup.

Annual revenue rose consistently for four straight years, from KRW 77.1 billion in 2022 to KRW 113.9 billion in 2023, KRW 133.3 billion in 2024, and KRW 185.9 billion in 2025, showing clear top-line expansion.

Operating profit, however, swung from gains of KRW 0.9 billion in 2022 and KRW 1.3 billion in 2023 to a sharp loss of KRW 6.9 billion in 2024, and continued as a loss of KRW 2.0 billion in 2025, with the operating margin improving somewhat from negative 5.2% to negative 1.1% but still remaining in negative territory.

On the net income side, after a large loss of KRW 14.3 billion attributable to owners in 2022, the company posted net losses of KRW 2.3 billion in 2023, KRW 4.8 billion in 2024, and KRW 4.5 billion in 2025, marking four consecutive years of net losses.

On a quarterly basis, after posting revenue of KRW 45.65 billion, an operating loss of KRW 0.80 billion, and a net loss of KRW 2.50 billion in Q2 2025, the company turned operating profitable in Q3 2025 with revenue of KRW 52.14 billion and operating profit of KRW 0.35 billion, yet still posted a net loss of KRW 0.49 billion, while Q4 2025 saw revenue of KRW 53.94 billion and an operating loss of KRW 0.49 billion alongside a small net profit of KRW 0.08 billion, illustrating a pattern where operating and net results moved in different directions.

In Q1 2026, revenue seasonally declined to KRW 44.04 billion but net profit rose sharply to KRW 2.64 billion, and in Q2 2026 revenue reached KRW 54.97 billion with operating profit of KRW 0.18 billion and net profit of KRW 1.98 billion, showing both revenue and net income improving together.

This recurring divergence between net income and operating results stems from fair-value gains and losses on convertible bonds and share-price-linked derivatives in prior periods, a structural feature that amplifies non-operating profit volatility tied to share price movements.

Over the trailing four quarters (Q3 2025 through Q2 2026), cumulative net income attributable to owners totaled KRW 4.21 billion, marking a departure from the large net loss periods of the past.

Even so, operating profit continued to alternate between gains and losses across the same period, leaving the stabilization of core business profitability as an ongoing task separate from revenue growth.

Korea's pharmaceutical distribution market continues to see steady demand growth driven by an aging population and rising chronic disease prevalence, and competition persists among distributors seeking to strengthen market position through differentiated services and product mixes within a market concentrated among large wholesalers.

The growing trend of purchasing medicines through online channels provides a favorable environment for e-commerce-based distribution platforms like BlueMTec.

In particular, competition in the GLP-1 obesity drug market has intensified as Eli Lilly Korea's Mounjaro launched domestically following Wegovy and Saxenda, with Lilly expanding its distribution network through direct supply contracts with a separate group of 30 to 40 companies including Geo Young.

This also illustrates that BlueMTec is unlikely to hold an exclusive position within the GLP-1 distribution network.

In the aesthetics segment, products from domestic botulinum toxin and filler manufacturers such as Hugel, LG Chem, Medytox, and Bio-Plus are increasingly supplied to clinics through online distribution channels, intensifying competition for product diversification among distribution platforms.

Overall, the industry is in a revenue growth phase, but margin structures tend to fluctuate with cost burdens typical of distribution businesses, and individual distributors' profitability can diverge depending on product mix and negotiating power.

In an April 2026 IR disclosure, BlueMTec stated that both revenue and operating profit improved by more than 30% year-over-year, and Wegovy-related revenue is reported to have expanded rapidly from about KRW 1 billion in March 2026 to roughly KRW 9 billion in May 2026.

Against this backdrop, Hana Securities projected in a June 2026 report that, based on the expansion of GLP-1 obesity drugs and aesthetics business, revenue could surpass KRW 200 billion this year with operating profit reaching breakeven, and forecast non-reimbursed and aesthetics revenue growing from KRW 37.6 billion last year to KRW 102.2 billion this year.

The number of items sold on BluePharmKorea increased from 25,607 to 27,809 as of Q1 2026 following the Wegovy launch, reflecting ongoing product diversification.

Hana Securities also cited the potential for new members acquired through GLP-1 obesity drugs to become active users, which could support future expansion into advertising, job-recruiting platforms, and AI-based value-added services.

The company has stated it is pursuing a transition toward becoming an omnichannel marketing agency through expanded member services on its BlueDoc medical staff platform and growth of its advertising business.

These outlooks, however, reflect a specific brokerage's estimates, and actual achievement will need to be confirmed through future quarterly earnings disclosures.